ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022
Evaluation of the Latent Tuberculosis Care Cascade Among Public Health Clinics in the United States.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- Optimizing Latent Tuberculosis Treatment Strategies Among Immigrants From High-Burden Settings.medRxiv : the preprint server for health sciences · 2026Article
- Uncovering Household Tuberculosis Infection Testing and Care Patterns Using a Novel Bioinformatics Linkage Strategy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Pre-screening village tuberculosis notification rates and the yield of interferon-gamma release assay testing in a rural health-examination campaign in Xinjiang, China.Frontiers in public health · 2026Article
- The Role of Electronic Medical Record Automation in Latent Tuberculosis Screening and Treatment in a Large Health System.Open forum infectious diseases · 2025Article
- Identifying Gaps in Tuberculosis Preventive Care for Non-U.S.-born Persons at Community Health Clinics in the United States.Open forum infectious diseases · 2025Article
- Improving tuberculosis infection treatment completion among pregnant and postpartum women.Journal of clinical tuberculosis and other mycobacterial diseases · 2025Article
- Health Impact and Cost-Effectiveness of Testing and Treatment of Mycobacterium Tuberculosis Infection Among Asian and Hispanic Persons With Diagnosed Diabetes in the United States.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2025Article
- Social Vulnerability Modifies the Effects of Geographic Proximity on Engagement in Latent Tuberculosis Infection Care in a United States Safety Net Healthcare Network.Open forum infectious diseases · 2025Article
- Genotyped cluster investigations versus standard contact tracing: comparative impact on latent tuberculosis infection cascade of care in a low-incidence region.BMC infectious diseases · 2025Article
- Real-World Status in the Treatment of Latent Tuberculosis Infection in People Living with HIV in Korea.Infection & chemotherapy · 2024Article
- Evaluation of the Tuberculosis Infection Care Cascade Among Pregnant Individuals in a Low-Tuberculosis-Burden Setting.Open forum infectious diseases · 2024Article
- Factors Associated With the Discontinuation of Two Short-Course Tuberculosis Preventive Therapies in Programmatic Settings in the United States.Open forum infectious diseases · 2024Article
- Comparison of Tuberculin Skin Testing and Interferon-γ Release Assays in Predicting Tuberculosis Disease.JAMA network open · 2024Article
- US Guidelines Fall Short on Short-Course Tuberculosis-Preventive Therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Diagnosis and management of tuberculosis infection in inclusion health populations in London.BMC infectious diseases · 2024Article
- Article
- Using Electronic Health Record Data to Measure the Latent Tuberculosis Infection Care Cascade in Safety-Net Primary Care Clinics.AJPM focus · 2023Article
- Latent Tuberculosis Screening Cascade for Non-US-Born Persons in a Large Health System.Open forum infectious diseases · 2023Article
- Latent Tuberculosis Infection Treatment Practices in Two Large Integrated Health Systems in California, 2009-2018.Open forum infectious diseases · 2023Article
- Latent Tuberculosis Treatment among Hard-to-Reach Ethiopian Immigrants: Nurse-Managed Directly Observed versus Self-Administered Isoniazid Therapy.Tropical medicine and infectious disease · 2023Article
Corrections and comments
- Commented on by
Authors and funding
17 authors at 11 institutions in 1 country.
Funding
Abstract
backgroundTuberculosis (TB) elimination within the United States will require scaling up TB preventive services. Many public health departments offer care for latent tuberculosis infection (LTBI), although gaps in the LTBI care cascade are not well quantified. An understanding of these gaps will be required to design targeted public health interventions.
methodsWe conducted a cohort study through the Tuberculosis Epidemiologic Studies Consortium (TBESC) within 15 local health department (LHD) TB clinics across the United States. Data were abstracted on individuals receiving LTBI care during 2016-2017 through chart review. Our primary objective was to quantify the LTBI care cascade, beginning with LTBI testing and extending through treatment completion.
resultsAmong 23 885 participants tested by LHDs, 46% (11 009) were male with a median age of 31 (interquartile range [IQR] 20-46). A median of 35% of participants were US-born at each site (IQR 11-78). Overall, 16 689 (70%) received a tuberculin skin test (TST), 6993 (29%) received a Quantiferon (QFT), and 1934 (8%) received a T-SPOT.TB; 5% (1190) had more than one test. Among those tested, 2877 (12%) had at least one positive test result (3% among US-born, and 23% among non-US-born, P < .01). Of 2515 (11%) of the total participants diagnosed with LTBI, 1073 (42%) initiated therapy, of whom 817 (76%) completed treatment (32% of those with LTBI diagnosis).
conclusionsSignificant gaps were identified along the LTBI care cascade, with less than half of individuals diagnosed with LTBI initiating therapy. Further research is needed to better characterize the factors impeding LTBI diagnosis, treatment initiation, and treatment completion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.